Effective cancer therapy through immunomodulation

Annual Review of Medicine

Volumn 57, Issue , 2006, Pages 65-81

  Waldmann, Thomas A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer vaccines; CTLA 4; IL 15; Immunological checkpoints; Monoclonal antibodies; Tregs

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CANCER VACCINE; CD4 ANTIGEN; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR REJECTION ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CANCER VACCINES; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 32944474058     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.56.082103.104549     Document Type: Review

References (69)

1. Köhler G, Milstein C. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-97
2. Ehrlich P. 1956. On immunity with special reference to cell life: Croonian lecture. In The Collected Papers of Paul Ehrlich: Immunology and Cancer Research, ed. B Himmelweir, pp. 148-92. London: Pergamon
3. Miller RA, Maloney DG, Warnke R, et al. 1982. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N. Engl. J. Med. 306:517-22
4. Waldmann TA. 1991. Monoclonal antibodies in diagnosis and therapy. Science 252:1657-62
5. Carter P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1:118-29
6. Gura T. 2002. Therapeutic antibodies: magic bullets hit the target. Nature 417:584-86
7. Waldmann TA. 2003. Immunotherapy: past, present and future. Nat. Med. 9:269-77
8. von Mehren M, Adams GP, Weiner LM, et al. 2003. Monoclonal antibody therapy for cancer. Annu. Rev. Med. 54:343-69
9. Stacy KM. 2005. Therapeutic mAbs: saving lives and making billions. The Scientist 19:17-19
10. Morris JC, Waldmann TA. 2000. Advances in interleukin-2 receptor targeted treatment. Ann. Rheum. Dis. 59:109-14
11. Maloney DG, Liles TM, Czerwinsri DK, et al. 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-66
12. Baselga J, Norton L, Albanell J, et al. 1998. Recombinant humanized anti-HER2 antibody (Herceptin™) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825-31
13. 131I Tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352:441-49
14. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-40
15. Waldmann T. 2003. ABCs of radioisotopes used for radioimmunotherapy: alpha and beta- emitters. Leuk. Lymphoma 44:S107-13
16. Mir SS, Richter BW, Duckett CS. 2000. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96:4307-12
17. Clynes RA, Towers TL, Presta LG, et al. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6:443-46
18. Zhang M, Zhang Z, Garmestani K, et al. 2004. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Cancer Res. 64:5825-29
19. Lode HN, Reisfeld RA. 2000. Targeted cytokines for cancer immunotherapy. Immunol. Res. 21:279-88
20. Sievers EL, Larson RA, Stadtmauer EA, et al. 2001. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19:3244-54
21. Kreitman RJ, Wilson WH, White JD, et al. 2000. Phase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol. 18:1622-36
22. 21a. Witzig TE, Gordon LI, Cabanillas F, et al. 2002. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20:2453-63
23. Axworthy DB, Reno JM, Hylarides MD, et al. 2000. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA 97:1802-07
24. Zhang M, Yao Z, Garmestani K, et al. 2002. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood 100:208-16
25. Denny WA. 2004. Tumor-activated prodrugs-a new approach to cancer therapy. Cancer Invest. 22:604-19
26. Presta LG, Chen H, O'Connor SJ, et al. 1997. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:4593-99
27. Kwon ED, Foster BA, Hurwitz AA, et al. 1999. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen (CTLA-4) blockade immunotherapy. Proc. Natl. Acad. Sci. USA 96:15074-79
28. Coiffier B, Lepage E, Briere J, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:235-42
29. Coley W. 1896. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and bacillus prodigious with a report of 160 cases. Johns Hopkins Hosp. Bull. 7:157-62
30. Rosenberg SA, Yang JC, Restifo NP. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10:909-15
31. Boon T, Cerottini JC, Van den Eynde B, et al. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337-65
32. Pardoll DM. 2002. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2:227-38
33. Rosenberg SA. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281-87
34. Srivastava PK. 2000. Immunotherapy of human cancer: lessons from mice. Nat. Immunol. 1:363-66
35. Bendandi M, Gocke CD, Kobrin CB, et al. 1999. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5:1171-77
36. Krackhardt AM, Witzens M, Harig S, et al. 2002. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100:2123-31
37. Rosenberg SA, White DE. 1996. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J. Immunother. Emphasis Tumor Immunol. 19:81-94
38. Berzofsky JA, Ahlers JD, Belyakov IM. 2001. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1:209-19
39. Melero I, Schuford W, Newby S, et al. 1977. Monoclonal antibodies against the 4-IBB T- cell activation molecule eradiate established tumors. Nat. Med. 3:682-88
40. Hodge JW, Poole DJ, Aarts WM, et al. 2003. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res. 63:7942-49
41. Emens LA, Jaffee EM. 2003. Cancer vaccines: an old idea comes of age. Cancer Biol. Ther. 2:S161-68
42. Hodi FS, Mihm MC, Soiffer RJ, et al. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100:4712-17
43. Rosenberg SA, Yang JC, Topalian SL, et al. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907-13
44. Waldmann TA, Dubois S, Tagaya Y. 2001. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14:105-10
45. Phan GQ, Yang JC, Sherry RM, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4-blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100:8372-77
46. Leach DR, Krummel MF, Allison JP. 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734-36
47. Hurwitz AA, Foster BA, Kwon ED, et al. 2000. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60:2444-48
48. Freeman GJ, Long AJ, Iwai Y, et al. 2000. Engagement of PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:1027-34
49. Dong H, Strome SE, Salomao DR, et al. 2002. Tumor-associated B7-H1 promotes T cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:793-800
50. Iwai Y, Ishida M, Tanaka Y, et al. 2002. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99:12293-98
51. + regulatory T cells and their therapeutic potential. Annu. Rev. Med. 57: In press
52. + T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211-18
53. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. 2001. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-32
54. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-62
55. Shevach EM. 2000. Regulatory T cells in autoimmunity. Anna. Rev. Immunol. 18:423-49
56. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164:183-90
57. Curiel TJ, Coukos G, Zou L, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-49
58. Lenardo MJ. 1996. Fas and the art of lymphocyte maintenance. J. Exp. Med. 183:721-24
59. + regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201:723-35
60. Sadlack B, Kuhn R, Schorle H, et al. 1994. Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and 4. Eur. J. Immunol. 24:281-84
61. Marks-Konczalik J, Dubois S, Losi JM, et al. 2000. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. USA 97:11445-50
62. + T cells in vivo by IL-15. Immunity 8:591-99
63. + memory T cells by opposing cytokines. Science 288:675-78
64. Kobayashi H, Dubois S, Sato N, et al. 2005. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood 105:721-27
65. Oh S, Berzofsky JA, Burke DS, et al. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. USA 100:3392-97
66. + T cells. Proc. Natl. Acad. Sci. USA 101:15154-59
67. Tarabe M, Matsui S, Naben-Trauth N, et al. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1:515-20
68. Gorelik L, Flavell RA. 2002. Transforming growth factor-beta in T-cell biology. Nat. Rev. Immunol. 2:46-53
69. Gorelik L, Flavell RA. 2001. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. 7:1118-22